BioTrace Medical touts real-world data from Tempo temporary lead

BioTrace Medical today released data from real-world experiences with its Tempo temporary pacing lead, touting no dislodgements or perforations and reliable pace capture during and after the procedure. The real-world experiences as well as 2 live cases were presented during the Transcatheter Valve Therapies 2017 in Chicago this week. In a presentation, Dr. Tamim Nazif of the NewYork-Presbyterian/Columbia University Medical Center released data from real-world experiences, including 3 cases from their Medical Center and several hundred other cases which reported no device-related adverse events, no perforations and dislodgements and an overall highly favorable operator feedback. “Our real-world experience with the Tempo Lead is consistent with the excellent results of the New Zealand first-in-human study demonstrating the safety and reliable performance of the device. The Tempo Lead may improve the safety of TAVR and other structural heart procedures by reducing complications like cardiac perforation, loss of pacing capture, and valve embolization. There may also be opportunities with the Tempo Lead to reduce the length of ICU stay, expedite recovery, and reduce permanent pacemaker implantation with a strategy of watchful waiting in patients with transient conduction disturbances,” Dr. Nazif said in a prepared release. Results from a separate multi-center study of 25 patients demonstrated no device related adverse evetns, dislogements and sustained ventricular arrh...
Source: Mass Device - Category: Medical Devices Authors: Tags: Cardiac Assist Devices Cardiac Implants Cardiovascular Clinical Trials BioTrace Medical Source Type: news